AIDSPub Date : 2024-10-01Epub Date: 2024-08-29DOI: 10.1097/QAD.0000000000003980
Melanie R Nicol, Halima Dawood, Jennifer F Hoy
{"title":"Deconvoluting the contribution of antiretroviral choice in weight gain.","authors":"Melanie R Nicol, Halima Dawood, Jennifer F Hoy","doi":"10.1097/QAD.0000000000003980","DOIUrl":"https://doi.org/10.1097/QAD.0000000000003980","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"38 12","pages":"1794-1795"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2024-10-01Epub Date: 2024-06-25DOI: 10.1097/QAD.0000000000003961
Jonathan M King, Timothy Dobbins, Phillip Keen, Vincent J Cornelisse, Mark Stoové, Steven J Nigro, Jason Asselin, Nasra Higgins, Limin Mao, Htein Linn Aung, Kathy Petoumenos, Skye McGregor
{"title":"Trends in HIV testing and HIV stage at diagnosis among people newly diagnosed with HIV.","authors":"Jonathan M King, Timothy Dobbins, Phillip Keen, Vincent J Cornelisse, Mark Stoové, Steven J Nigro, Jason Asselin, Nasra Higgins, Limin Mao, Htein Linn Aung, Kathy Petoumenos, Skye McGregor","doi":"10.1097/QAD.0000000000003961","DOIUrl":"10.1097/QAD.0000000000003961","url":null,"abstract":"<p><strong>Objective: </strong>To identify groups more likely to be referred for HIV testing because of symptomatic presentation rather than as part of asymptomatic screening.</p><p><strong>Design: </strong>A retrospective analysis of Australian National HIV Registry (NHR) surveillance data including sociodemographic and clinical data, as well as reasons for HIV test.</p><p><strong>Methods: </strong>Using notification records from 2017 to 2022, we summarised reasons for testing leading to an HIV diagnosis. Reasons for testing were combined with clinical status at diagnosis to derive HIV testing categories: testing while symptomatic; asymptomatic HIV screening; seroconversion; and other test reason. We stratified these categories by stage of HIV at diagnosis with late-stage HIV defined as a CD4 + cell count <350 cells/μl at time of diagnosis.</p><p><strong>Results: </strong>Among 4134 HIV notifications with at least one reason for testing recorded, STI screening was the predominant reason for test referral (38%), followed by HIV indicative symptoms (31%), and risk behaviour (13%). By testing category, people aged 50 years or older (24%), people with HIV attributed to heterosexual sex (21%), people born in sub-Saharan Africa (19%), and women (17%) had lower levels of asymptomatic screening. More late-stage HIV diagnoses resulted from testing while symptomatic (58%) compared with asymptomatic screening (25%).</p><p><strong>Conclusions: </strong>Older people and heterosexuals may not access HIV focused healthcare where HIV screening is routinely offered. Instead, HIV testing opportunities may arise in other settings. By normalising HIV testing and offering low-cost HIV screening in a range of settings, it may be possible to facilitate earlier HIV diagnoses, better health outcomes, and reduced onward transmission.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1774-1782"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11356677/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2024-10-01Epub Date: 2024-06-25DOI: 10.1097/QAD.0000000000003970
Mary Clare Masters, Katherine Tassiopoulos, Yajing Bao, Kunling Wu, Susan L Koletar, Leah H Rubin, Jingyan Yang, Edgar T Overton, Scott Letendre, Todd T Brown, Kristine M Erlandson, Frank J Palella
{"title":"Risk factors for progression from prediabetes to diabetes among older people with HIV.","authors":"Mary Clare Masters, Katherine Tassiopoulos, Yajing Bao, Kunling Wu, Susan L Koletar, Leah H Rubin, Jingyan Yang, Edgar T Overton, Scott Letendre, Todd T Brown, Kristine M Erlandson, Frank J Palella","doi":"10.1097/QAD.0000000000003970","DOIUrl":"10.1097/QAD.0000000000003970","url":null,"abstract":"<p><strong>Objective: </strong>Risk factors for progression from prediabetes mellitus (pre-DM) to diabetes mellitus (DM) among people with HIV (PWH) receiving modern antiretroviral therapy (ART) require better characterization.</p><p><strong>Design: </strong>AIDS Clinical Trials Group (ACTG) A5322 (HAILO) was an observational cohort study of PWH ≥40 years old. Participants initiated ART through ACTG randomized clinical trials.</p><p><strong>Methods: </strong>We used Cox proportional hazards regression models to identify risk factors for development of DM among HAILO participants with pre-DM.</p><p><strong>Results: </strong>Among 1035 HAILO participants, 74 (7%) had pre-DM at entry and another 679 (66%) developed pre-DM during follow-up. Of 753 PWH with pre-DM, 167 (22%) developed DM. In multivariable models, the risk of developing DM was greater with higher BMI, lower CD4 count (≤200 cells/mm 3 ), hypertriglyceridemia, or higher waist circumference at pre-DM diagnosis ( P < 0.01).</p><p><strong>Conclusion: </strong>Rates of pre-DM and progression to DM remain high among virally suppressed PWH receiving modern ART regimens. Traditional risks for DM, such as higher BMI or waist circumference, are associated with increased risk of incident DM among PWH with pre-DM. The association between lower CD4 + and progression to DM suggests a role for advanced immunodeficiency and inflammation. Further investigation of interventions aimed at preventing DM among PWH with pre-DM is needed. Optimizing prevention and treatment for DM may be an intervenable opportunity to improve long-term outcomes for PWH.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1740-1748"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2024-10-01Epub Date: 2024-08-29DOI: 10.1097/QAD.0000000000003982
Luiz Fernando Gouvêa-E-Silva
{"title":"Challenges in clinical monitoring of people with HIV: evolution from prediabetes mellitus to diabetes mellitus.","authors":"Luiz Fernando Gouvêa-E-Silva","doi":"10.1097/QAD.0000000000003982","DOIUrl":"https://doi.org/10.1097/QAD.0000000000003982","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"38 12","pages":"1796-1798"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2024-10-01Epub Date: 2024-05-31DOI: 10.1097/QAD.0000000000003950
Henning Drechsler, Colby Ayers, Ikwo Oboho, Ngozi Enwerem, John Hanna, Christopher Clark, Ellen Kitchell, Mamta Jain, Amneris Luque, Roger Bedimo
{"title":"Choice of antiretroviral therapy has low impact on weight gain.","authors":"Henning Drechsler, Colby Ayers, Ikwo Oboho, Ngozi Enwerem, John Hanna, Christopher Clark, Ellen Kitchell, Mamta Jain, Amneris Luque, Roger Bedimo","doi":"10.1097/QAD.0000000000003950","DOIUrl":"10.1097/QAD.0000000000003950","url":null,"abstract":"<p><strong>Objective: </strong>Antiretroviral therapy (ART) containing integrase inhibitors (INSTIs) and/or tenofovir alafenamide (TAF) has been associated with greater weight gain. Yet few studies have delineated between exposure to 'anchor' drugs [protease inhibitors (PI), nonnucleoside reverse transcriptase inhibitors (NNRTI) or INSTIs] and exposure to nucleoside reverse transcriptase inhibitors (NRTIs).</p><p><strong>Design: </strong>In this cohort of antiretroviral drug-naive patients who initiated ART from 2008-2022, we analyzed BMI gain for eight contemporary 'anchor' drugs and three contemporary NRTIs during the first 3 years of ART. We censored patients if they stopped, switched, or added another antiretroviral drug to their regimen.</p><p><strong>Methods: </strong>We used generalized estimating equations (GEE) to assess the association between BMI gain and choice of ART and a nonlinear mixed model for the marginal coefficients of determination. We adjusted for time, baseline demographic and HIV-characteristics, and time-updated HIV and substance use-related variables.</p><p><strong>Results: </strong>The median BMI gain in 4 194 patients over 3 years was + 1.9 kg/m 2 [interquartile range (IQR) 0.1-4.1]. Most patients were black (55%) and men (77%). Multivariable modeling from 20 528 BMI measurements revealed that the type of ART accounted for just 9% of the predicted BMI change. Only efavirenz (EFV) and tenofovir disoproxil fumarate (TDF) were independently associated with (lower) weight gain but no differences were observed between INSTIs, PIs, and rilpivirine, or between TAF and abacavir.</p><p><strong>Conclusion: </strong>The choice of initial ART had little impact on weight gain. INSTIs or TAF were not independently associated with weight change after ART initiation, but EFV and TDF were.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1731-1739"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2024-10-01Epub Date: 2024-06-20DOI: 10.1097/QAD.0000000000003965
Samuel C Russo, Mollie W Ockene, Allison K Arpante, Julia E Johnson, Hang Lee, Mabel Toribio, Takara L Stanley, Colleen M Hadigan, Steven K Grinspoon, Kristine M Erlandson, Lindsay T Fourman
{"title":"Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors.","authors":"Samuel C Russo, Mollie W Ockene, Allison K Arpante, Julia E Johnson, Hang Lee, Mabel Toribio, Takara L Stanley, Colleen M Hadigan, Steven K Grinspoon, Kristine M Erlandson, Lindsay T Fourman","doi":"10.1097/QAD.0000000000003965","DOIUrl":"10.1097/QAD.0000000000003965","url":null,"abstract":"<p><strong>Objective: </strong>Tesamorelin is the only FDA-approved therapy to treat abdominal fat accumulation in people with HIV (PWH). Phase III clinical trials were conducted prior to the introduction of integrase inhibitors (INSTIs), which are now a mainstay of HIV antiretroviral therapy.</p><p><strong>Design: </strong>We leveraged a randomized double-blind trial of 61 PWH and metabolic dysfunction-associated steatotic liver disease to evaluate the efficacy and safety of tesamorelin 2 mg once daily vs. identical placebo among participants on INSTI-based regimens at baseline.</p><p><strong>Methods: </strong>In the parent clinical trial, visceral fat cross-sectional area, hepatic fat fraction, and trunk-to-appendicular fat ratio were quantified using magnetic resonance imaging, proton magnetic resonance spectroscopy, and dual-energy x-ray absorptiometry, respectively, at baseline and 12 months. Metabolic and safety outcomes were compared between treatment arms.</p><p><strong>Results: </strong>Among 38 participants on INSTI-based regimens at baseline, 15 individuals on tesamorelin and 16 individuals on placebo completed the 12-month study. Tesamorelin led to significant declines in visceral fat (median [interquartile range]: -25 [-93, -2] vs. 14 [3, 41] cm 2 , P = 0.001), hepatic fat (-4.2% [-12.3%, -2.7%] vs. -0.5% [-3.9%, 2.7%], P = 0.01), and trunk-to-appendicular fat ratio (-0.1 [-0.3, 0.0] vs. 0.0 [-0.1, 0.1], P = 0.03). Tesamorelin was well tolerated with a similar frequency of adverse events, including hyperglycemia, between groups.</p><p><strong>Conclusions: </strong>The current analysis provides the first dedicated data on the efficacy and safety of tesamorelin among PWH on INSTI-based regimens. Despite the association of INSTI use with weight gain and adipose tissue dysfunction, tesamorelin had beneficial effects on body composition with no exacerbation of glycemic control.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1758-1764"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11365754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2024-10-01Epub Date: 2024-07-17DOI: 10.1097/QAD.0000000000003979
Cassandra R Duffy, Julie M Herlihy, Ethan Zulu, Lawrence Mwananyanda, Leah Forman, Tim Heeren, Christopher J Gill, Megan Harper, Roma Chilengi, Roy Chavuma, Barbara Payne-Lohman, Donald M Thea
{"title":"Preterm birth among women with HIV: impact of preconception cART initiation.","authors":"Cassandra R Duffy, Julie M Herlihy, Ethan Zulu, Lawrence Mwananyanda, Leah Forman, Tim Heeren, Christopher J Gill, Megan Harper, Roma Chilengi, Roy Chavuma, Barbara Payne-Lohman, Donald M Thea","doi":"10.1097/QAD.0000000000003979","DOIUrl":"10.1097/QAD.0000000000003979","url":null,"abstract":"<p><strong>Objective: </strong>To examine the risk of preterm birth (PTB) and small for gestational age (SGA) among women with HIV compared to women without HIV. Secondary objectives were to explore the role of maternal immune activation (IA) and effect of cART timing on these outcomes.</p><p><strong>Design: </strong>Prospective observational cohort.</p><p><strong>Setting: </strong>Urban government-run clinic at Chawama Hospital in Lusaka, Zambia.</p><p><strong>Participants: </strong>A total of 1481 women with and without HIV with singleton pregnancies enrolled before 26 weeks' gestation by ultrasound dating.</p><p><strong>Methods: </strong>From August 2019 to November 2022, pregnant women were enrolled in a 1 : 1 ratio of HIV infection. Maternal baseline clinical factors were collected, as well as CD4 + , viral load and CD8 + T-cell IA in women with HIV. Birth outcomes were also collected. The association of HIV-exposure and cART timing on outcomes was assessed by multivariable logistic regression. The independent role of IA was determined by mediation analysis.</p><p><strong>Main outcome measures: </strong>PTB (<37 weeks) and SGA.</p><p><strong>Results: </strong>There were 38 fetal deaths and 1230 singleton live births. Maternal HIV infection was associated with PTB [adjusted odds ratio (AOR) 1.60, 95% confidence interval (CI) 1.11-2.32] and to a lesser extent SGA (AOR 1.29, 95% CI 0.98-1.70). Maternal cART timing impacted these associations, with highest risk in women who started cART after conception (PTB AOR 1.77, 95% CI 1.09-2.87, SGA AOR 1.52, 95% CI 1.04-2.22). Maternal IA was not associated with PTB independent of HIV infection.</p><p><strong>Conclusions: </strong>HIV is associated with PTB. Risk of PTB and SGA was highest in women with HIV who started cART in pregnancy, a modifiable risk factor.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":"1749-1757"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11356690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141625710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2024-09-30DOI: 10.1097/QAD.0000000000004028
Daniele Pastori, Francesco Del Sole, Tommaso Brogi, Maria Del Ben, Caterina Fimiani, Claudio Maria Mastroianni, Ivano Mezzaroma
{"title":"Epicardial fat and liver stiffness by ARFI elastography in people living with Human Immunodeficiency Virus type 1 (HIV-1) infection without liver disease.","authors":"Daniele Pastori, Francesco Del Sole, Tommaso Brogi, Maria Del Ben, Caterina Fimiani, Claudio Maria Mastroianni, Ivano Mezzaroma","doi":"10.1097/QAD.0000000000004028","DOIUrl":"https://doi.org/10.1097/QAD.0000000000004028","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the association between increased epicardial fat thickness (EFT) and liver stiffness measurement (LSM), as assessed by elastography in people living with Human Immunodeficiency Virus type 1 (HIV-1) infection (PWH).</p><p><strong>Methods: </strong>91 PWH on effective antiretroviral treatment (ART) were enrolled. EFT was measured by transthoracic echocardiography. Liver steatosis was evaluated by ultrasound Hamaguchi criteria and LSM by elastography with Acoustic Radiation Force Impulse (ARFI) Tecnique. LSM ≥8 Kpa was suggestive of clinically relevant fibrosis.</p><p><strong>Results: </strong>Mean age was 54.3 years and 27.5% were women. EFT correlated with HIV-1 infection duration (rS 0.252, p = 0.016), age at study entry (rS 0.527, p < 0.001), BMI (rS 0.363, p < 0.001), waist circumference (rS 0.549, p < 0.001), HDL (rS -0.391, p < 0.001), triglycerides (rS 0.375, p < 0.001), Hamaguchi score (rS 0.279, p = 0.007), right lobe of the liver (rS 0.259, p = 0.014), Left ventricular mass/Body surface area (rS 0.220, p = 0.036).A LSM ≥8 Kpa was found in 20.9% of PWH, more commonly in those with EFT above the median >5.6 mm (30.4% vs 11.1%, p = 0.038). LSM significantly correlated with EFT (rS 0.274, p = 0.009), CD4+ cells (rS -0.320, p = 0.003) and nadir of CD4+ cells (rS -0.292, p = 0.007).In a subgroup (n = 53), an HOMA-IR index >2.33 identified increased EFT, (AUC 0.73, 95%CI 0.59-0.84, p = 0.001) while an HOMA-IR >3.27 predicted increased LSM (AUC 0.76, 95%CI 0.62-0.87, p = 0.005).</p><p><strong>Conclusions: </strong>PWH with increased EFT have worse metabolic profile and a high proportion of clinically relevant fibrosis at ARFI elastography, despite normal liver function tests. The HOMA-IR index might be used to identify PWH with increased EFT and liver fibrosis.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142339223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2024-09-23DOI: 10.1097/QAD.0000000000004023
Michael J A Reid, Rebecca Bunnell, Marie Davis, Hillary Carter, Maureen Bartee, Tatiana Marrufo, John Nkengasong
{"title":"Sustaining two decades of PEPFAR's response to global HIV/AIDS: mitigating the impact of climate threats.","authors":"Michael J A Reid, Rebecca Bunnell, Marie Davis, Hillary Carter, Maureen Bartee, Tatiana Marrufo, John Nkengasong","doi":"10.1097/QAD.0000000000004023","DOIUrl":"10.1097/QAD.0000000000004023","url":null,"abstract":"","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142278969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
AIDSPub Date : 2024-09-18DOI: 10.1097/qad.0000000000004017
Jennifer O Lam,Craig E Hou,Catherine Lee,Zahra Samiezade-Yazd,Tory Levine,Michael A Horberg,Derek D Satre,Michael J Silverberg
{"title":"Hypertension control and risk of age-associated dementia in people with hiv infection.","authors":"Jennifer O Lam,Craig E Hou,Catherine Lee,Zahra Samiezade-Yazd,Tory Levine,Michael A Horberg,Derek D Satre,Michael J Silverberg","doi":"10.1097/qad.0000000000004017","DOIUrl":"https://doi.org/10.1097/qad.0000000000004017","url":null,"abstract":"OBJECTIVEHypertension is a major risk factor for dementia, but sustained blood pressure control is difficult to achieve. We evaluated whether inadequately controlled hypertension may contribute to excess dementia risk among people with HIV.DESIGNRetrospective cohort study.METHODSWe studied demographically matched people with and without HIV between 7/1/2013 and 12/31/2021 who were ≥50 years old and had a hypertension diagnosis but no dementia diagnosis. Hypertension control was calculated using a disease management index (DMI) which captured degree and duration above the hypertension treatment goals of systolic blood pressure (SBP) <140 mmHg and diastolic blood pressure (DBP) <90 mmHg. DMI values ranged from 0% to 100% (perfect control); hypertension was considered \"inadequately controlled\" if DMI<80% (i.e., in control for <80% of the time). Annual, time-updated DMI was calculated for SBP and DBP. Associations of SPB and DPB control with incident dementia were evaluated using extended Cox regression models.RESULTSThe study included 3,099 hypertensive people with HIV (mean age: 58.3 years, 90.2% men) and 66,016 people without HIV. Each year of inadequate SBP control was associated with greater dementia risk in both people with HIV (adjusted hazard ratio [aHR] = 1.26, 0.92-1.64) and people without HIV (aHR = 1.27 (1.21-1.33); p-interaction = 0.85). Similarly, inadequate DBP control was associated with greater dementia risk in both people with HIV (aHR = 1.43, 0.90-1.95) and people without HIV (aHR = 1.71, 1.50-1.93; p-interaction = 0.57).CONCLUSIONSFindings suggest the association of inadequate hypertension control with greater dementia risk is similar by HIV status. Stronger associations of DBP control with dementia merits further investigation.","PeriodicalId":7502,"journal":{"name":"AIDS","volume":"44 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142261358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}